Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Buyout target Medivation says cancer drug could be "best in class"
Buyout target Medivation says cancer drug could be "best in class"
Buyout target Medivation says cancer drug could be "best in class"
Submitted by
admin
on July 6, 2016 - 9:52pm
Source:
Yahoo/Reuters
News Tags:
Medivation
talazoparib
PARP inhibitors
Sanofi
M&A
Headline:
Buyout target Medivation says cancer drug could be "best in class"
Do Not Allow Advertisers to Use My Personal information